Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)

Next Previous
Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 1034020 (Primary) ; BI 1034020 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 30 May 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.record.
  • 19 Mar 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
  • 30 Oct 2013 Boehringer Ingelheim has dosed the first healthy volunteers in this trial, according to an Ablynx media release. Results are expected during the second half of 2014.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top